Related Experiment Video
Updated: May 3, 2026
09:09
Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
Published on: September 20, 2016
14.6K
Novel GPCR paradigms at the μ-opioid receptor
G L Thompson1, E Kelly, A Christopoulos
1Drug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Vic., Australia.
British Journal of Pharmacology
|January 28, 2014
Summary
Discovering safer analgesics involves exploring biased agonism and allosterism at the mu-opioid receptor. These advanced approaches aim to improve opioid-based pain treatments by minimizing adverse side effects.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Neuroscience
Background:
- Opioids are crucial analgesics but cause significant side effects, limiting their use.
- Drug discovery seeks to enhance opioid treatments for better therapeutic profiles.
- Opioid receptors are G protein-coupled receptors (GPCRs).
Purpose of the Study:
- To review progress in identifying and quantifying biased agonism and allosterism at the mu-opioid receptor.
- To explore the implications of these mechanisms for developing safer analgesics.
Main Methods:
- Review of current scientific literature on biased agonism and allosterism in opioid receptors.
- Analysis of identification and quantification strategies for these receptor modulation mechanisms.
Main Results:
- Biased agonism is observed across all opioid receptor family members.
- The first allosteric modulators of opioid receptors have been recently identified.
- Challenges remain in quantifying biased agonism for drug discovery.
Conclusions:
- Biased agonism and allosterism offer promising pathways for developing improved opioid analgesics.
- Further research is needed to overcome challenges in quantifying these effects.
- Targeting mu-opioid receptor functional selectivity can lead to safer pain management strategies.
Related Concept Videos
01:22Opioid Receptors: Overview
7.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.2K
01:25Analgesia and Pain Management
3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
01:30Transducer Mechanism: G Protein–Coupled Receptors
9.0K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
9.0K
01:12GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
01:15G Protein-coupled Receptors
14.1K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
14.1K
01:15G Protein-coupled Receptors
2.4K
2.4K